1. SCYNEXIS, Inc. SCYNEXIS announces FDA approval of BREXAFEMME® (ibrexafungerp tablets) as the first and only oral non-azole treatment for vaginal yeast infections [media release]. https://www.scynexis.com/. 2 Jun 2021.
2. SCYNEXIS, Inc. BREXAFEMME® (ibrexafungerp tablets) for oral use: US prescribing information. 2021. https://www.brexafemme.com/. Accessed 24 Jun 2021.
3. SCYNEXIS, Inc. SCYNEXIS reports first quarter 2021 financial results and provides corporate update [media release]. http://www.scynexis.com. 17 May 2021.
4. SCYNEXIS, Inc. SCYNEXIS Inc. announces research collaboration with Merck & Co. Inc. for discovery of novel anti-infective agents [media release]. 26 Jun 2002.
5. SCYNEXIS, Inc. SCYNEXIS gains worldwide rights to novel antifungal compound [media release]. http://www.scynexis.com. 29 May 2013.